Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-04-27 | Gabriel Leung was appointed a director in March 2011. Mr. Leung is a 25+ year veteran of the pharmaceutical and biotechnology industry. |
| 2012-04-27 | The current members of the Audit Committee are: Laura A. Philips (Chair), Douglas G. Watson, Robert B. Ladd and Gabriel Leung, each of whom is "independent" within the meaning of the NASDAQ listing rules and otherwise meet the financial statement proficiency requirements of the NASDAQ listing rules. The Board has determined that a majority of our incumbent directors, namely, Harold S. Koplewicz, M.D., Robert B. Ladd, Gabriel Leung, Laura A. Philips, Roger G. Stoll and Douglas G. Watson are "independent" directors within the meaning of the NASDAQ listing rules. The Audit Committee met seven times in 2011. The Audit Committee has a written charter, which is available on our website; go to www.delcath.com, click on "Investors," then "Corporate Governance." The current members of the Compensation and Stock Option Committee are Roger G. Stoll (Chair), Robert B. Ladd and Gabriel Leung, each of whom is "independent" within the meaning of the NASDAQ listing rules. During 2011, the Compensation and Stock Option Committee met 13 times. The Compensation and Stock Option Committee has a written charter, which is available on our website; go to www.delcath.com, click on "Investors," then "Corporate Governance." The current members of the Nominating and Corporate Governance Committee are Douglas G. Watson (Chair), Laura A. Philips and Roger G. Stoll, each of whom is "independent," within the meaning of the NASDAQ listing rules. During 2011, the Nominating and Corporate Governance Committee met seven times. The Nominating and Corporate Governance Committee has a written charter, which is available on our website; go to www.delcath.com, click on "Investors," then "Corporate Governance." The following table sets forth the compensation awarded to, earned by or paid to each director who served on our Board of Directors in 2011, other than Eamonn P. Hobbs, our Chief Executive Officer and President. Details of Mr. Hobbs' compensation are set forth under the heading "Executive Compensation—Summary Compensation Table." Gabriel Leung received $44,500 in fees earned or paid in cash, $49,999 in stock awards and $75,021 in options awards, totaling $169,520. |
| 2013-04-22 | Gabriel Leung was appointed a director in March 2011. ... The current members of the Audit Committee are: Laura A. Philips (Chair), Douglas G. Watson, Tasos G. Konidaris and Gabriel Leung. ... The current members of the Compensation and Stock Option Committee are Roger G. Stoll (Chair), Laura A. Brege and Gabriel Leung. ... Gabriel Leung Fees Earned or Paid in Cash: 66,500, Stock Awards: 50,000, Total: 116,500. |
| 2014-04-30 | Gabriel Leung was appointed Chairman of the Board in September 2013. The Transition Committee members include Gabriel Leung. Director compensation for Gabriel Leung in 2013 was $93,282. |
Data sourced from SEC filings. Last updated: 2025-12-07